EARLY DEVELOPMENT IN FRAGILE X SYNDROME: IMPLICATIONS FOR DEVELOPMENTAL SCREENING

被引:3
作者
Bailey, Donald B. [1 ]
Hazlett, Heather Cody [2 ]
Roberts, Jane E. [3 ]
Wheeler, Anne C. [2 ]
机构
[1] RTI Int, Social Stat & Environm Sci, Res Triangle Pk, NC USA
[2] Univ N Carolina, Carolina Inst Dev Disabil, Chapel Hill, NC USA
[3] Univ S Carolina, Dept Psychol, Columbia, SC 29208 USA
来源
INTERNATIONAL REVIEW OF RESEARCH IN DEVELOPMENTAL DISABILITIES: EARLY DEVELOPMENT IN NEUROGENETIC DISORDERS, VOL 40 | 2011年 / 40卷
关键词
FRONTAL-SUBCORTICAL CIRCUITS; MENTAL-RETARDATION PROTEIN; TISSUE-SPECIFIC EXPRESSION; FMR-1 FULL MUTATION; AUTISTIC BEHAVIOR; WHITE-MATTER; HEAD CIRCUMFERENCE; YOUNG-CHILDREN; MOUSE MODEL; HUMAN-BRAIN;
D O I
10.1016/B978-0-12-374478-4.00004-6
中图分类号
G76 [特殊教育];
学科分类号
040109 ;
摘要
Fragile X syndrome (FXS), the most common inherited form of intellectual disability, is not obvious at birth. The average age of diagnosis is around 36 months, a figure that has remained unchanged over the past decade. A primary challenge has been the lack of a definitive profile of early development in FXS. This chapter reviews the research that has been conducted relevant to this question. Research has been severely hampered by the fact that in the absence of population screening of newborns, it is virtually impossible to identify a sufficient and representative sample of infants to study. The research that has been conducted suggests that critical neurobiological processes are almost certainly affected in utero and in the early months of development. Consequently, many but not all males with FXS show delays during the latter part of the first year of life. This statement would be less true for females and for premutation carriers. We predict that a best case scenario for promoting earlier identification would be through regular developmental screening of infants in pediatric practice and rapid referral for genetic testing of any infant with developmental delays. Even if these policies could be implemented effectively, however, diagnosis of FXS would, at best, occur at an average age of 16-18 months. More research on early development is needed to further enhance understanding of clinical symptoms during the first year of life, but thus far it appears that a signature FXS profile will be difficult to identify. Population screening, such as newborn screening, will be the only realistic approach to identifying all children with FMR1 gene mutations.
引用
收藏
页码:75 / 108
页数:34
相关论文
共 50 条
  • [31] Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome
    Berry-Kravis, Elizabeth M.
    Lindemann, Lothar
    Jonch, Aia E.
    Apostol, George
    Bear, Mark F.
    Carpenter, Randall L.
    Crawley, Jacqueline N.
    Curie, Aurore
    Des Portes, Vincent
    Hossain, Farah
    Gasparini, Fabrizio
    Gomez-Mancilla, Baltazar
    Hessl, David
    Loth, Eva
    Scharf, Sebastian H.
    Wang, Paul P.
    Von Raison, Florian
    Hagerman, Randi
    Spooren, Will
    Jacquemont, Sebastien
    NATURE REVIEWS DRUG DISCOVERY, 2018, 17 (04) : 280 - 298
  • [32] Developmental expression of the neuroligins and neurexins in fragile X mice
    Lai, Jonathan K. Y.
    Doering, Laurie C.
    Foster, Jane A.
    JOURNAL OF COMPARATIVE NEUROLOGY, 2016, 524 (04) : 807 - 828
  • [33] Acoustic properties of early vocalizations in infants with fragile X syndrome
    Hamrick, Lisa R.
    Seidl, Amanda
    Tonnsen, Bridgette L.
    AUTISM RESEARCH, 2019, 12 (11) : 1663 - 1679
  • [34] Early white-matter abnormalities of the ventral frontostriatal pathway in fragile X syndrome
    Haas, Brian W.
    Barnea-Goraly, Naama
    Lightbody, Amy A.
    Patnaik, Swetapadma S.
    Hoeft, Fumiko
    Hazlett, Heather
    Piven, Joseph
    Reiss, Allan L.
    DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2009, 51 (08) : 593 - 599
  • [35] Fragile X Syndrome Therapeutics S(C)TEP through the Developmental Window
    Bhattacharya, Aditi
    Klann, Eric
    NEURON, 2012, 74 (01) : 1 - 3
  • [36] Early developmental alterations in GABAergic protein expression in fragile X knockout mice
    Adusei, Daniel C.
    Pacey, Laura K. K.
    Chen, Duke
    Hampson, David R.
    NEUROPHARMACOLOGY, 2010, 59 (03) : 167 - 171
  • [37] IMPROVING THE TRAJECTORY OF DEVELOPMENT IN YOUNG CHILDREN WITH FRAGILE X SYNDROME
    Hagerman, R.
    Greiss-Hess, L.
    Chitwood, K.
    Hanson, A.
    Polussa, J.
    Bishop, L.
    Siyahian, S.
    Chechi, T.
    Li, C. -S
    Mundy, P.
    JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2014, 58 (10) : 884 - 885
  • [38] Development of mavoglurant and its potential for the treatment of fragile X syndrome
    Gomez-Mancilla, Baltazar
    Berry-Kravis, Elizabeth
    Hagerman, Randi
    von Raison, Florian
    Apostol, George
    Ufer, Mike
    Gasparini, Fabrizio
    Jacquemont, Sebastien
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2014, 23 (01) : 125 - 134
  • [39] The Psychiatric Presentation of Fragile X: Evolution of the Diagnosis and Treatment of the Psychiatric Comorbidities of Fragile X Syndrome
    Tranfaglia, Michael R.
    DEVELOPMENTAL NEUROSCIENCE, 2011, 33 (05) : 337 - 348
  • [40] Channelopathies and dendritic dysfunction in fragile X syndrome
    Brager, Darrin H.
    Johnston, Daniel
    BRAIN RESEARCH BULLETIN, 2014, 103 : 11 - 17